Drug intelligence / Profile preview

Part A - single rising dose 1

Development stage: Phase 1
Lead developer: Beite Xinqi Biomedical
Modality: Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration: Inhalation

Overview

Part A - single rising dose 1 refers to a specific intervention of the investigational drug XQ-001, which is administered via nebulized inhalation. This intervention is part of a randomized, double-blind, placebo-controlled Phase Ia clinical study designed to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of XQ-001 in healthy Chinese adult subjects. The drug is being developed by Brilliant Inspiration Biotherapeutics for the treatment of Idiopathic Pulmonary Fibrosis.

Other names: Inhaled XQ-001

Targets

ROCK2 (Rho-associated coiled-coil containing protein kinase 2)

Beyond the preview

Go deeper on Part A - single rising dose 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Part A - single rising dose 1.